RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Axsome Therapeutics Stock

Axsome Therapeutics ROCE 2024

Axsome Therapeutics ROCE

-1.21

Ticker

AXSM

ISIN

US05464T1043

WKN

A2AA7B

In 2024, Axsome Therapeutics's return on capital employed (ROCE) was -1.21, a -25.8% increase from the -1.64 ROCE in the previous year.

Axsome Therapeutics Aktienanalyse

What does Axsome Therapeutics do?

Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of severe psychiatric and neurological disorders. The company was founded in 2012 and is headquartered in New York City. The history of Axsome Therapeutics began with the identification of a new molecule called AXS-05, which was developed as a potential antidepressant and treatment for Alzheimer's disease. The company utilized its proprietary technology platform to optimize the drug's properties and then began conducting clinical studies to evaluate the efficacy and safety of AXS-05 in patients with depression, Alzheimer's disease, and other neurological disorders. Axsome Therapeutics' business model is based on the identification and development of novel drug candidates through the use of knowledge about novel target molecules and innovative technologies. The company aims to rapidly and cost-effectively develop its drugs to quickly achieve commercial benefits from its developments. The company relies on collaboration with strategic partners and acquisitions for faster market entry. Axsome Therapeutics is divided into several business areas, each identifying and developing different drug candidates. For example, one area is the field of pain medicine, where the company is developing novel therapies for chronic pain and migraines. Another area is psychiatric disorders, where the company focuses on novel treatments for depression, anxiety disorders, bipolar disorder, and post-traumatic stress disorder. A third area is neurodegenerative diseases, where the company is researching new approaches to treating Alzheimer's disease and Parkinson's disease. Axsome Therapeutics has several products in the pipeline at various stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III clinical trials for the treatment of depression and Alzheimer's disease. AXS-05 has been deemed safe and well-tolerated in previous studies and has shown significant improvement in symptoms in patients with severe depression. In studies on Alzheimer's and dementia, the medication showed preliminary improvement in specific disease symptoms. In addition to AXS-05, the company is also working on the development of AXS-12, a drug for the treatment of narcolepsy, and AXS-09, a combination of two known drugs for the treatment of migraines. In summary, Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development of novel therapies for the treatment of severe psychiatric and neurological disorders. The company has developed a proprietary technology platform that allows for cost-effective optimization and rapid development of drug candidates. Axsome Therapeutics is divided into several business areas and has several products in the pipeline at different stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III trials for the treatment of depression and Alzheimer's disease. Axsome Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Axsome Therapeutics's Return on Capital Employed (ROCE)

Axsome Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Axsome Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Axsome Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Axsome Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Axsome Therapeutics stock

What is the ROCE (Return on Capital Employed) of Axsome Therapeutics this year?

The ROCE of Axsome Therapeutics is -1.21 undefined this year.

How has the ROCE (Return on Capital Employed) of Axsome Therapeutics developed compared to the previous year?

The ROCE of Axsome Therapeutics has increased by -25.8% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Axsome Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Axsome Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Axsome Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Axsome Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Axsome Therapeutics impact the company?

An increase in the ROCE of Axsome Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Axsome Therapeutics affect the company?

A decrease in ROCE of Axsome Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Axsome Therapeutics?

Some factors that can affect Axsome Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Axsome Therapeutics so important for investors?

The ROCE of Axsome Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Axsome Therapeutics take to improve the ROCE?

To improve the ROCE, Axsome Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Axsome Therapeutics pay?

Over the past 12 months, Axsome Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Axsome Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Axsome Therapeutics?

The current dividend yield of Axsome Therapeutics is .

When does Axsome Therapeutics pay dividends?

Axsome Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Axsome Therapeutics?

Axsome Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Axsome Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Axsome Therapeutics located?

Axsome Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Axsome Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Axsome Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Axsome Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Axsome Therapeutics in the year 2023?

In the year 2023, Axsome Therapeutics distributed 0 USD as dividends.

In which currency does Axsome Therapeutics pay out the dividend?

The dividends of Axsome Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Axsome Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Axsome Therapeutics

Our stock analysis for Axsome Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Axsome Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.